ArticlePloS one2016
Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- The Kidney in the Shadow of Cirrhosis: A Critical Review of Renal Failure.Biomedicines · 2025Review
- Risk factors for hospital readmission among patients with cirrhosis and ascites in China: a retrospective observational study.The Journal of international medical research · 2024Observational
- Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.Life (Basel, Switzerland) · 2022Review
- Article
- Altered pro-inflammatory and anti-inflammatory plasma cytokines levels in children with Down's syndrome: A meta-analysis.Journal of family medicine and primary care · 2021Article
- Risk Stratification Score to Predict Readmission of Patients With Acute Decompensated Cirrhosis Within 90 Days.Frontiers in medicine · 2021Article
- Roles Played by Biomarkers of Kidney Injury in Patients with Upper Urinary Tract Obstruction.International journal of molecular sciences · 2020Review
- Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study.Digestive diseases and sciences · 2020Article
- Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers.Clinical and translational gastroenterology · 2020Observational
- Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis.BioMed research international · 2020Review
- Ability of the Short Physical Performance Battery Frailty Index to Predict Mortality and Hospital Readmission in Patients with Liver Cirrhosis.International journal of hepatology · 2019Article
- Role of monocyte chemoattractant protein-1 in liver fibrosis with transient myeloproliferative disorder in down syndrome.Hepatology communications · 2018Article
- Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure.Biomedical reports · 2018Article
- Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections.The American journal of gastroenterology · 2017Article
- Perioperative management of the bleeding patient.British journal of anaesthesia · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledMCP-1 (monocyte chemoattractant protein-1) is a proinflammatory cytokine involved in chemotaxis of monocytes. In several diseases, such as acute coronary syndromes and heart failure, elevated MCP-1 levels have been associated with poor outcomes. Little is known about MCP-1 in cirrhosis.
aimTo investigate the relationship between MCP-1 and outcome in decompensated cirrhosis.
methodsProspective study of 218 patients discharged from hospital after an admission for complications of cirrhosis. Urine and plasma levels of MCP-1 and other urine proinflammatroy biomarkers: osteopontin(OPN), trefoil-factor3 and liver-fatty-acid-binding protein were measured at admission. Urine non-inflammatory mediators cystatin-C, β2microglobulin and albumin were measured as control biomarkers. The relationship between these biomarkers and the 3-month hospital readmission, complications of cirrhosis, and mortality were assessed.
results69 patients(32%) had at least one readmission during the 3-month period of follow-up and 30 patients died(14%). Urine MCP-1 and OPN levels, were associated with 3-month probability of readmission (0.85 (0.27-2.1) and 2003 (705-4586) ug/g creat vs 0.47 (0.2-1.1) and 1188 (512-2958) ug/g creat, in patients with and without readmission, respectively; p<0.05; median (IQR)). Furthermore, urine levels of MCP-1 were significantly associated with mortality (1.01 (1-3.6) vs 0.5 (0.2-1.1) μg/g creat, in dead and alive patients at 3 months; p<0.05). Patients with higher levels of urine MCP-1 (above percentile 75th) had higher probability of development of hepatic encephalopathy, bacterial infections or AKI. Urine MCP-1 was an independent predictive factor of hospital readmission and combined end-point of readmission or dead at 3 months. Plasma levels of MCP-1 did not correlated with outcomes.
conclusionUrine, but not plasma, MCP-1 levels are associated with hospital readmission, development of complications of cirrhosis, and mortality. These results suggest that in cirrhosis there is an inflammatory response that is associated with poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.